Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Oslo University Hospital hereby announce research awards in the following two catagories for 2017:
- Excellent Researcher Award (one prize, 300.000 NOK)
- Early Career Award (two prizes of 150.000 NOK each)
The candidate must be employed by Oslo University Hospital or University of Oslo, and be a member of a research group at Oslo University Hospital/University of Oslo.
Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention
Nadja Katheder and collaborators in the lab of Tor Erik Rusten, the Department of Molecular Cell Biology, and CCB has published an article entitled "Microenvironmental autophagy supports tumor growth", in an advanced online publication 11th of January in the journal Nature (journal impact factor 41.46).
It is known that transformed tumor cells rewire growth and metabolism to support their own growth. How these changes occur in animals, however are poorly understood. In the published study, Katheder and co-workers show how malignant tumors coerce neighboring microenvironmental cells to support their own growth.
The findings have been subject to news coverage by the Norwegian national broadcasting corporation (NRK).
New insight into the origin of disseminated tumor cells in breast cancer published in Genome Biology
Elen Kristine Møller, postdoc at the Department of Cancer Genetics, studied during her PhD project the fate of disseminated tumor cells (DTCs). In a collaborative study among OUS, University of Chicago, University of Leuven and the Francis Crick Institute it is revealed that breast cancer cells break away and spread to other parts of the body relatively late on in breast tumor development.
The findings are published in the December 9th issue of Genome Biology (journal impact factor 11.3), in an article entitled "Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing".
Update: The story has become the "Editors Choice" in the January 4th issue of Science Translational Medicine.
The Norsk Hydro’s Fund for Cancer Research Lecture January 16th 10:45 - 12:00 in the Auditorium (K-building) at Montebello will be held by the prominent scientist Channing J. Der from UNC Lineberger Comprehensive Cancer Center, Chapel Hill.
Title of his talk:
"Drugging undruggable RAS for cancer treatment"
Dr. Channing J. Der is recognized internationally for his contribution to the discovery and research of the Ras family of oncoproteins.
In the Nature Methods (journal impact factor 25.3) January 2017 issue “Epitranscriptome analysis” is presented as the method of the year. In recent years, it has become clear that RNA molecules, including mRNAs, can be dynamically modified. Thus, this allows for a new strategy for gene regulation with vital biological consequences. Epitranscriptome analysis relates to methods that can profile RNA modifications in a sequence specific manner. In a commentary to this discovery, Klungland and co-workers from Department of Microbiology and Department of Gynecology, OUS, discuss the role of such modifications for the maturation of sperm and egg (meiosis) and pluripotent cells.
In a new study published in Oncotarget, Hauge et al. found an explanation for why combined inhibition of Chk1 and Wee1 gives synergistic anti-cancer effects.
Inhibitors of Wee1 and Chk1 kinases are currently in clinical trials in combination with radiation- or chemotherapy, due to their roles in inhibition of cell cycle checkpoints and DNA repair. Recent preclinical studies have shown synergistic effects of simultaneous Wee1 and Chk1 inhibition, but the mechanisms behind this synergy were not known.
The board of the South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has distributed financial resources to new research projects for 2017. Of the in total 568 incoming applications 121 new projects were granted support.
A substantial amount of the resources goes to young researchers. Support is given to a number og doctoral and post doctoral stipendiates, as well as to researcher grants and career grants. The latter category is for young outstanding researchers planning to establish an independent research group.
As part of the collaboration between Oslo Cancer Cluster and Ullern high shool, a total of 40 students visited six different laboratories at the Oslo University Hospital and the National Institute for Public Health last week. A journalist from Framtida.no interviewed the six students who visited the Department for Tumor biologi. Researchers Siri Tveito and Karen-Marie Heintz guided them through immunoflourescence, PCR, gel electrophoresis and other techniques in the lab, and the students were eager to learn about the life of a cancer researcher.
First author Kristina Berg Lorvik and senior author Alexandre Corthay
Collaborative efforts by researchers at the Department of Immunology and the Department of Pathology revealed the unexpected potential of tumor-specific Th2 cells for cancer immunotherapy by adoptive cell transfer (ACT) in mice.
The study was published in the December 1st 2016 issue of Cancer Research, the flagship journal of the American Association for Cancer Research. An immunofluorescence microscopy image from the paper was selected to illustrate the journal cover.
Two skilful and talented scientists have recently been appointed group leaders at the Department of Molecular Cell Biology at the Institute for Cancer Research.
Jorrit Enserink (left) heads the "Dynamic responses to cell stress" group. He was previously affiliated to the Department of Microbiology at the Division of Laboratory Medicine, OUS.
Tor Erik Rusten is heading the "Tumor-Host Biology" group, and has been promoted from his previous project group leader status at the same department.
Excellent Researcher Award and Early Career Award 2017
Jan 16, 2017
Antimicrobial resistance - how bad is the situation in the world of virus, fungus and mycoplasma?
Jan 11, 2017
Jan 11, 2017
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Microenvironmental autophagy promotes tumour growth
Nature (in press)
Properdin binding to complement activating surfaces depends on initial C3b deposition
Proc Natl Acad Sci U S A (in press)
NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture
Cell Rep, 18 (1), 82-92
More selected publications